Elevated Intraocular Pressure In Open Angle Glaucoma Or Ocular Hypertension Therapeutics
1. Omlonti patent expiration
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10774072 | OCUVEX THERAP | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(9 years from now) | |
| US8648097 | OCUVEX THERAP | Pyridylaminoacetic acid compound |
Oct, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295946 | OCUVEX THERAP | NA |
Jan, 2035
(9 years from now) | |
| US12290511 | OCUVEX THERAP | NA |
Dec, 2038
(12 years from now) | |
| US11666563 | OCUVEX THERAP | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(13 years from now) | |
| US11197849 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10702511 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10179127 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US9415038 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| USRE48183 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US11793798 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10765750 | OCUVEX THERAP | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US8685986 | OCUVEX THERAP | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Dosage: SOLUTION
More Information on Dosage
OMLONTI family patents
